follow us
disclaim warranti liabil
due number sourc inform servic acquisdata pti ltd servic obtain
inher hazard electron distribut may delay omiss inaccuraci inform
servic acquisdata pti ltd affili agent sale repres distributor licensor
warrant accuraci complet current merchant abil fit particular purpos
inform servic avail acquisdata pti ltd servic event acquisdata pti ltd
affili agent sale repres distributor licensor liabl license anyon els loss
injuri caus whole part conting beyond control procur compil interpret edit write
report deliv inform servic acquisdata pti ltd servic event acquisdata
pti ltd affili agent sale repres distributor licensor liabl license anyon els
decis made action taken license relianc upon inform servic consequenti
special similar damag even advis possibl damag license agre liabil
acquisdata pti ltd affili agent sale repres distributor licensor aris kind
legal claim whether contract tort otherwis way connect acquisdata pti ltd servic shall
exceed amount license paid use acquisdata pti ltd servic twelv month immedi
preced event give rise claim
first-quart world-wide sale billion increas percent includ percent posit
impact foreign exchang
first-quart ep reflect billion aggreg charg relat format
collabor eisai first-quart non-gaap ep
compani narrow rais full-year revenu rang billion billion
includ approxim percent posit impact foreign exchang
compani lower ep rang narrow rais full-year
non-gaap ep rang includ approxim percent posit impact
foreign exchang
result phase studi present publish new england
journal medicin show keytruda combin pemetrex platinum chemotherapi
reduc risk death half compar chemotherapi alon first-lin treatment advanc
data review regulatori author unit state europ
tuesday may edt
kenilworth -- busi -- merck nyse known msd outsid unit state
canada today announc financi result first quarter
merck strong start year driven keytruda gardasil bridion anim health said
kenneth frazier merck chairman ceo provid good momentum continu execut
pillar growth look deliv innov medicin vaccin address unmet need patient around
world
million except ep amount
non-gaap net incom exclud item list
non-gaap ep exclud item list
world-wide sale billion first quarter increas percent compar first
quarter includ percent posit impact foreign exchang
gener accept account principl earn per share assum dilut ep first
quarter reflect billion aggreg charg relat format collabor eisai
co ltd eisai non-gaap ep first quarter exclud acquisition- divestiture-rel
cost restructur cost charg relat eisai collabor referenc certain item
oncolog
advanc
keytruda
pembrolizumab compani therapi lynparza olaparib parp inhibitor co-develop
co-commerci astrazeneca compani recent present pivot phase data keytruda
american associ cancer research annual meet addit merck eisai enter
strateg collabor world-wide co-develop co-commerci lenvima lenvatinib mesyl
oral avail tyrosin kinas inhibitor discov eisai eisai merck develop commerci
lenvima jointli monotherapi combin keytruda
merck announc result phase trial evalu keytruda combin
pemetrex cisplatin carboplatin first-lin treatment metastat nonsquam non-smal cell lung
cancer nsclc find show combin significantli improv overal surviv os reduc
risk death half compar chemotherapi alon pre-specifi exploratori analys os benefit
observ regardless express three categori evalu result
present plenari session aacr annual meet simultan public new
england journal medicin nejm
develop program
base data food drug administr fda grantedprior review
supplement biolog licens applic sbla keytruda combin pemetrex platinum
chemotherapi first-lin treatment patient metastat nonsquam nsclc pdufa date
sept addit merck announc follow valid european medicin agenc
ema central review process begun compani type ii variat seek approv
keytruda combin pemetrex platinum cisplatin carboplatin first-lin treatment
patient metastat nonsquam nsclc applic accept review base os
progression-fre surviv data phase trial
merck announc phase trial evalu keytruda monotherapi first-lin
treatment local advanc metastat nsclc includ nonsquam squamou histolog met
primari endpoint os interim analysi conduct independ data monitor committe
demonstr treatment keytruda result significantli longer os platinum-bas
chemotherapi carboplatin plu paclitaxel carboplatin plu pemetrex patient tumor
proport score tp percent
fda accept review new sbla keytruda treatment previous treat patient
recurr metastat head neck squamou cell carcinoma base data phase
trial fda set pdufa date dec
merck european organis research treatment cancer eortc announc find
phase trial investig keytruda adjuv therapi resect
high-risk stage melanoma result studi show keytruda significantli prolong recurrence-
free surviv reduc risk diseas recurr death percent compar placebo overal
studi popul result present open plenari session aacr annual meet
simultan public nejm
merck incyt corpor announc extern data monitor committe edmc review
pivot phase studi result evalu epacadostat combin
keytruda patient unresect metastat melanoma determin studi meet
primari endpoint improv overal popul compar keytruda monotherapi studi
second primari endpoint os also expect reach statist signific base result
recommend edmc studi stop safeti profil observ echo-
consist observ previous report studi epacadostat
combin keytruda
fda accept new sbla grant prioriti review keytruda treatment patient
advanc cervic cancer diseas progress chemotherapi fda set pdufa date
sbla keytruda treatment adult pediatr patient refractori primari mediastin b-
cell lymphoma relaps two prior line therapi remain review
fda fda extend pdufa date day juli due addit data analys
submit merck
committe medicin product human use ema adopt posit opinion recommend
market author lynparza use mainten therapi patient platinum-sensit
relaps high grade epitheli ovarian fallopian tube primari periton cancer complet
respons partial respons platinum-bas chemotherapi
ema valid review market author applic lynparza use patient
deleteri suspect deleteri brca-mut human epiderm growth factor receptor
metastat breast cancer previous treat chemotherapi neoadjuv adjuv
metastat set first regulatori submiss parp inhibitor breast cancer europ
januari lynparza approv fda use treatment brca-mut
metastat breast cancer becom first parp inhibitor approv beyond ovarian cancer
fda grant orphan drug design selumetinib mek inhibitor co-develop
astrazeneca treatment neurofibromatosi type
merck viralyt limit sign definit agreement propos merck acquir
viralyt australian publicli trade compani focus oncolyt immunotherapi treatment rang
cancer upon complet transact merck gain full right cavatak viralyticss
compani also continu advanc vaccin hiv infecti diseas pipelin
merck announc begin two phase studi investig polyval conjug vaccin
prevent pneumococc diseas first studi evalu safeti toler
immunogen follow pneumococc vaccin polyval one year later healthi adult subject
year age older second studi evalu safeti toler immunogen
follow pneumococc vaccin polyval administ eight week later adult infect hiv
result phase phase studi present intern societi pneumococci
merck present data robust hiv pipelin includ doravirin late-stag investig non-
nucleosid revers transcriptas inhibitor investig nucleosid revers transcriptas
transloc inhibitor confer retrovirus opportunist infect doravirin current
review ema fda pdufa date oct unit state
merck announc pivot phase studi relebactam compani investig beta-lactamas
inhibitor combin imipenem/cilastatin demonstr favor overal respons treatment
certain imipenemnon-suscept bacteri infect primari endpoint lower treatment-emerg
nephrotox kidney toxic secondari endpoint compar colistin colistimeth sodium plu
imipenem regimen base result compani plan submit new drug applic fda
follow tabl reflect sale compani top pharmaceut product well sale anim health
million
m-m-r ii varivax
first-quart pharmaceut sale increas percent billion includ percent posit impact
foreign exchang increas primarili driven growth oncolog hospit acut care diabet
partial off-set lower sale virolog on-going impact loss market exclus sever
growth oncolog driven signific increas sale keytruda reflect compani continu
launch new indic global strong momentum treatment patient nsclc
keytruda approv first-lin set addit oncolog sale reflect allianc
revenu million relat lynparza
growth hospit acut care reflect strong global demand bridion sugammadex inject mg/ml
medicin revers neuromuscular blockad induc rocuronium bromid vecuronium bromid
growth diabet driven januvia sitagliptin janumet sitagliptin metformin medicin
help lower blood sugar adult type diabet reflect growth intern market driven higher
demand partial off-set price pressur sale declin unit state reflect continu price pressur
partial off-set volum growth well favor adjust rebat reserv
perform vaccin primarili driven higher sale gardasil papillomaviru quadrival
type vaccin recombin gardasil human papillomaviru vaccin
recombin vaccin prevent certain cancer diseas caus hpv reflect growth asia
pacif primarili due commerci launch china growth europ partial off-set lower sale
unit state decreas gardasil/gardasil sale unit state driven declin volum
due continu transit two-dos regimen vaccin perform neg affect
signific decreas sale zostavax zoster vaccin live vaccin prevent herp zoster
primarili due approv competitor product receiv preferenti recommend
advisori committe immun practic octob compani anticip futur sale
zostavax continu unfavor affect competit
pharmaceut sale growth quarter partial off-set lower sale virolog larg reflect
signific declin zepati elbasvir grazoprevir medicin treatment chronic hepat viru
genotyp infect due increas competit declin patient volum compani expect
continu
pharmaceut sale growth quarter also partial off-set on-going impact loss unit
state market exclus zetia ezetimib late vytorin ezetimibe/simvastatin april
medicin lower cholesterol biosimilar competit remicad infliximab treatment
inflammatori diseas compani market territori europ loss exclus
cancida caspofungin acet inject antifung europ
anim sale total billion first quarter increas percent compar first
quarter includ percent posit impact foreign exchang growth driven higher sale
livestock product primarili rumin poultri product well higher sale companion anim product
first quarter anim health becam report segment result addit disclosur
requir relat segment perform includ segment profit anim health segment
profit million first quarter decreas percent compar million first
quarter
first-quart expens ep relat inform
tabl present select expens inform
million
acquisition-
materi product
market administr
research develop
materi product
market administr
research develop
gaap expens ep relat inform
gross margin percent first quarter compar percent first quarter
increas gross margin first quarter primarili driven lower net impact acquisition-
divestiture-rel cost restructur cost reduc gross margin percentag point first
quarter compar percentag point first quarter increas partial off-set
amort unfavor manufactur varianc part result june cyber-attack well
unfavor effect foreign exchang
market administr expens billion first quarter percent increas compar
first quarter increas primarili reflect unfavor effect foreign exchang higher
administr cost reflect priorit invest growth product
research develop expens billion first quarter compar billion
first quarter increas driven primarili billion aggreg charg relat format
collabor eisai unfavor effect foreign exchang increas clinic develop spend
invest earli drug develop partial off-set lower licens cost
incom expens net million incom first quarter compar million
incom first quarter incom expens net first quarter reflect gain
legal settlement recognit unreal gain secur result adopt new account
standard equiti invest
effect incom tax rate percent first quarter reflect unfavor impact
billion aggreg charg relat format eisai collabor tax benefit
gaap ep first quarter compar first quarter
non-gaap expens ep relat inform
non-gaap gross margin percent first quarter compar percent first
quarter decreas non-gaap gross margin predomin due amort unfavor
manufactur varianc part result june cyber-attack well unfavor effect
non-gaap market administr expens billion first quarter increas
percent compar first quarter increas non-gaap market administr expens
driven primarili unfavor effect foreign exchang higher administr cost reflect
priorit invest growth product
non-gaap expens billion first quarter percent decreas compar first
quarter decreas primarili reflect lower licens cost partial off-set unfavor effect
foreign exchang increas clinic develop spend invest earli drug develop
non-gaap incom expens net million incom first quarter compar
million incom first quarter non-gaap incom expens net first quarter
reflect gain legal settlement recognit unreal gain secur result adopt
new account standard equiti invest
non-gaap ep first quarter compar first quarter
reconcili non- net incom ep provid tabl follow
million except ep amount
non-gaap ep exclud item list
non-gaap net incom exclud item list
decreas increas net incom due exclud item
acquisition- divestiture-rel
aggreg charg relat format collabor eisai
net decreas increas incom tax
decreas increas net incom
merck narrow rais full-year revenu rang billion billion
includ approxim percent posit impact foreign exchang current exchang rate
merck lower full-year ep rang chang
ep rang reflect inclus charg relat collabor eisai merck narrow rais
full-year non-gaap ep rang includ approxim percent posit
impact foreign exchang current exchang rate non-gaap rang exclud acquisition- divestiture-
relat cost cost relat restructur program charg relat format collabor eisai
certain item
acquisdata proud host leagu estim want opportun win free
subscript join acquisdata media telecommun leagu
today merck global health care leader work help world well merck known msd outsid
unit state canada prescript medicin vaccin biolog therapi anim health
product merck work custom oper countri deliv innov health solut
merck also demonstr commit increas access health care far-reach polici program
partnership
acquisdata date busi intellig report cover develop world
report vast archiv corpor document list compani around world
aenova group one world lead compani pharmaceut healthcar industri europ
aenova one lead contract manufactur rang servic cover entir valu chain
develop manufactur common dosag form solid semi-solid liquid product group
medicin dietari supplement group oper site nine european countri asia usa
twelv site headquart locat germani aenova employe
 braun one world lead healthcar supplier braun four divis orient product
servic toward differ medic field hospit surgeri privat practic medic care doctor offic
bayer innov compani histori core compet field health care
agricultur develop new molecul use innov product solut improv health
human anim plant bayer research develop activ base profound understand
biochem process live organ
boehring ingelheim group one world lead pharmaceut compani headquart
ingelheim germani boehring ingelheim oper global affili employe
focu family-own compani found research develop manufactur market
new medic high therapeut valu human veterinari medicin
umbrella tecdax-list compani carl zeiss meditec ag one world lead
medic technolog compani medic technolog activ zeiss bundl carl zeiss ag hold
interest carl zeiss meditec ag jena germani parent compani carl zeiss meditec
group compris addit subsidiari carl zeiss meditec inc carl zeiss meditec iberia
desitin arzneimittel gmbh activ intern germani switzerland scandinavia eastern europ level
hamburg plant produc sophist product treatment neurolog psychiatr ill
offer larg number establish innov product especi core indic epilepsi
parkinson syndrom optim pharmacotherapi continu develop cooper
future-ori compani treat diseas central nervou system one desitin main area
activ invest
freseniu global healthcar group offer high-qual product servic dialysi hospit
outpati treatment employe countri around globe annual sale
exceed billion freseniu one world lead healthcar compani freseniu group includ
four independ oper busi segment one activ major growth area healthcar freseniu
medic world leader treat peopl chronic kidney failur freseniu helio germani largest
hospit oper freseniu kabi suppli essenti drug clinic nutrit product medic devic servic
help critic chronic ill patient freseniu vame plan develop manag healthcar facil
freseniu medic world largest integr provid product servic individu undergo
dialysi chronic kidney failur condit affect around million individu world-wide
network dialysi clinic north america europ latin america asia-pacif africa freseniu
medic provid dialysi treatment patient around globe freseniu medic also
world lead provid dialysi product hemodialysi machin dialyz relat dispos
grnenthal group independ family-own intern research-bas pharmaceut compani
headquart aachen germani grnenthal one five remain research-ori pharmaceut
compani headquart germani sustain invest research develop research
develop cost amount percent revenu grnenthal research develop
strategi concentr select field therapi state-of-the-art technolog compani focus
discov new way treat pain better effect fewer side-effect current therapi
human healthcar togeth
merz pharma independ intern aesthet neurotoxin compani research
develop capabl continu growth market leadership aesthet neurotoxin result
drive innov along focus strateg acquisit continu expand across area
busi due focus purpos approach includ organ inorgan growth privately-
held family-own compani histori believ take long-term view
morphosi develop hucal success antibodi librari technolog pharmaceut industri
success appli patent technolog morphosi becom leader field
therapeut antibodi one
pharmaceut partner morphosi built therapeut pipelin human antibodi drug
candid treatment cancer rheumatoid arthriti alzheim diseas name
on-going commit new antibodi technolog drug develop morphosi focus make
healthcar product tomorrow morphosi list frankfurt stock exchang symbol mor
hartmann group one lead european provid medic hygien product core
compet wound treatment wound dress negative-pressur wound therapi conform bandag
plaster incontin care dispos incontin brief pad well product skin care case
incontin infect protect surgic drape oper theatr cloth dispos surgic
instrument disinfect portfolio supplement product compress therapi first aid
compani headquart heidenheim germani whose prioriti market europ oper around
world employe hartmann group gener sale eur million
engin innov employ peopl compani provid healthcar germani
harmon qualiti medic care sound busi model good busi judgment
tada publicli trade intern compani focu healthcar market
perfect combin tradit innov attract cost
germani best intern locat research product distribut pharmaceut
except high level direct access intern renown scientist outstand research unit major
pharmaceut market make germani uniqu busi locat develop world popul
structur creat new challeng lead increas demand pharmaceut togeth
signific advanc medic biotechnolog research give pharmaceut industri new impetu
addit central locat heart europ germani offer excel well-develop nationwid
infrastructur modern transport network work coordin high-qual commun
energi infrastructur hundr thousand highli qualifi worker area medic technolog
pharmaceut technolog mechan engin enabl compani implement effici complex
product process pharmaceut compani germani also benefit close proxim lead
machin plant manufactur ensur continu product process reduc downtim germani
account approxim total product machineri plant europ
research develop
germani becom one world import countri clinic studi germani leader
industry-initi clinic studi europ second world-wide dens network univers faculti
well varieti research institut affili univers speak favor germani busi locat
benefit assess review negoti problem conflict
legislatur creat act restructur pharmaceut market amnog includ difficult
compon term mandatori discount price moratorium earli benefit assess directli
massiv impact exist busi model especi procedur earli benefit assess
establish process complex complic place question
facilit easier categor individu aspect procedur develop interact
inform graphic cooper rztezeitung illustr process earli benefit assess
includ parti involv result problem conflict
associ research-bas pharmaceut compani vfa
earli german associ research-bas pharmaceut compani vfa
vfa repres interest global leader research-bas pharmaceut compani
subsidiari affili compani healthcar research econom polici
german associ pharmaceut industri bpi
servic provid compani field biotechnolog herbal medicin homeopathy/anthroposophi
german associ produc
member member among pharmaceut industri associ
germani member primarili pharmaceut produc also pharmacist lawyer publish agenc
well market opinion research institut healthcar field
generika associ compani manufactur gener biosimilar product germani
generika member compani germani compani manufactur gener biosimilar product
togeth cover percent medicin drug requir statutori health insur fund
bundesverband der arzneimittel-herstel german medicin manufactur associ
repres interest pharmaceut industri germani compris intern compani well
local small medium enterpris sme compani membership lead trade organ
pharmaceut industri germani
cover entir rang industri landscap self-med medicin over-the-counter prescript
drug rx medic devic
advoc secur respons self-med profession medic pharmaceut advic
therefor strongli support statutori protect owner-oper pharmaci primari institut
addit commit free fair clean advertis promot principl regist
activ take part public health polici discuss compet refer public author
policymak institut german healthcar sector
member inform relev regulatori legisl procedur nation european level
offer scientif hands-on advic scientif servic organ widi
repres member european level brussels-bas aesgp associ european
self-med industri furthermor associ wsmi world self-med industri feder
member associ contin
work pharmaceut compani germani greatli hamper recent year due legisl
measur sever step tighten discount regul caus legal mandat manufactur discount
tripl sinc addit discount increas substanti recent year base individu agreement
overal manufactur receiv half sell price drug sector statutori
health insur report increas spend last year expenditur pharmaceut actual decreas
main driver behind spend pharmaceut price actual decreas year
increas consumpt result age societi avail new improv pharmaceut
treatment sever life-threaten diseas
third shi expenditur eur billion total eur billion spent hospit treatment togeth
expenditur care doctor eur billion percent pharmaceut eur billion percent
make anoth third eur billion spent administr cost increas mandatori manufactur
discount result percent decreas expenditur pharmaceut compar
associ research-bas pharmaceut compani vfa
acquisdata date busi intellig report cover develop world
report vast archiv corpor document list compani around world
